Pharmakotherapie der ADHS im Erwachsenenalter

D. Brummer; A. Ludolph; B. Connemann

doi:10.1055/s-0038-1628716

Nervenheilkunde, Table of Contents

Nervenheilkunde 2010; 29(01/02): 38-42
DOI: 10.1055/s-0038-1628716

Adhs

Schattauer GmbH

Pharmakotherapie der ADHS im Erwachsenenalter

Pharmacotherapy of ADHD in adults

D. Brummer

¹Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm

,

A. Ludolph

²Klinik für Kinderund Jugendpsychiatrie und Psychotherapie, Universitätsklinikum Ulm

,

B. Connemann

¹Klinik für Psychiatrie und Psychotherapie III, Universitätsklinikum Ulm

› Author Affiliations

Abstract

Zusammenfassung

Die Pharmakotherapie der Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung (ADHS) im Erwachsenenalter ist in der multimodalen Behandlung dieser Erkrankung ein wichtiger Baustein. Für die medikamentöse Behandlung stehen verschiedene Präparate zur Verfügung, die seit vielen Jahren in der Behandlung von betroffenen Kindern und Jugendlichen zum Einsatz kommen. Die deutschen Leitlinien empfehlen auch für die medikamentöse Therapie der von ADHS betroffenen Erwachsenen Methylphenidat als Medikament erster Wahl. Metaanalysen konnten zeigen, dass die Effektstärke im Erwachsenenalter allerdings etwas geringer als im Kindesund Jugendalter ist. Es sind seit einigen Jahren verschiedene Methylphenidatpräparate mit unterschiedlicher Wirkstofffreisetzung und Wirkdauer auf dem Markt. Alternativ steht unter anderem das nicht betäubungsmittelrezeptpflichtige Atomoxetin zur Verfügung, das insbesondere bei begleitender Ticerkrankung oder Abhängigkeitserkrankung Vorteile aufweist. Bisher ist keine Substanz für die Behandlung Erwachsener zugelassen, d. h. die medikamentöse Behandlung erfolgt nach wie vor “off label”. Die bei vielen erwachsenen ADHS-Patienten bestehenden Komorbiditäten machen oft eine Kombinationsbehandlung z. B. mit Antidepressiva erforderlich.

Summary

The pharmacological treatment of attention deficit hyperactivity disorder (ADHD) in adults is an integral part of the multimodal treatment indicated in this disorder. There are different substances available which are intensively studied and highly efficacious in affected children and adolescents. The German Psychiatric guidelines recommend methylphenidate as drug of first choice also for the treatment of adults with ADHD. Metaanalyses could show though that the effect size in adults is smaller than in children (1.0 vs. 0.49). For several years now, various methylphenidate formulations with different kinetic profiles are on the market. Alternatively, atomoxetine which is not a narcotic, scheduled controlled prescription drug, is available. Atomoxetine might have advantages in treatment of ADHD patients with comorbide tic disorders or substance abuse. No pharmaceutical substance is licensed for treatment of ADHD in adults in Germany, the pharmacological treatment is completely “off label”. The very common comorbidities in adult ADHD patients often make a combined treatment, e. g. with antidepressants, necessary.

Schlüsselwörter

ADHS bei Erwachsenen - Pharmakotherapie - Stimulanzien - Atomoxetin

Keywords

ADHD in adults - psychopharmacological treatment - stimulants - atomoxetine

Full Text

References

Literatur
1 Biederman J, Pliszka SR. Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents. J Pediatr 2008; 152 (03) 394-399.
2 Biederman J, Spencer TJ, Wilens TE. et al. SLI381.304 study group. Long-term safety and effectiveness of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr 2005; 10 (12 Suppl 20): 16-25.
3 Bradley C. The behavior of children receiving benzedrine. Am J Psychiatry 1937; 94: 577-585.
4 Ebert D, Krause J, Roth-Sackenheim C. ADHS im Erwachsenenalter – Leitlinien auf der Basis eines Expertenkonsensus mit Unterstützung der DGPPN. Nervenarzt 2003; 74: 939-946.
5 Faraone SV, Biederman J, Spencer T. et al. Efficacy of atomoxetine in adult attention-deficit/hyperactivity disorder: a drug-placebo response curve analysis. Behav Brain Funct 2005; 03: 1-16.
6 Faraone SV, Biederman J. Neurobiology of attention-deficit hyperactivity disorder. Biol Psychiatry 1998; 44 (10) 951-958.
7 Faraone SV, Doyle AE, Mick E. et al. Meta-analysis of the association between the 7-repeat allele of the dopamine D (4) receptor gene and attention deficit hyperactivity disorder. Am J Psychiatry 2001; 158 (07) 1052-1057.
8 Faraone SV, Spencer T, Aleardi M. et al. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2004; 24 (01) 24-29.
9 Gawin F, Kleber H. Pharmacologic treatments of cocaine abuse. Psychiatr Clin North Am 1986; 09 (03) 573-583.
10 Heath Jr CT, Wright HH, Batey SR. Attention deficit hyperactivity disorder: does it affect adults too?. South Med J 1990; 83 (12) 1396-1401.
11 Kinsbourne M, De Quiros GB, Tocci DRufo. Adult ADHD. Controlled medication assessment. Ann N Y Acad Sci 2001; 931: 287-296.
12 Koesters M, Becker T, Kilian R. et al. Limits of metaanalysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder. J Psychopharmacol 2009; 23 (07) 733-744.
13 Levin FR, Evans SM, McDowell DM. et al. Methylphenidate treatment for cocaine abusers with adult attention-deficit/hyperactivity disorder: a pilot study. J Clin Psychiatry 1998; 59 (06) 300-305.
14 Markowitz JS, Straughn AB, Patrick KS. Advances in the pharmacotherapy of attention-deficit-hyperactivity disorder: focus on methylphenidate formulations. Pharmacotherapy 2003; 23 (10) 1281-1299.
15 Masellis M, Basile VS, Muglia P. et al. Psychiatric pharmacogenetics: personalizing psychostimulant therapy in attention-deficit/hyperactivity disorder. Behav Brain Res 2002; 130 (1–2): 85-90.
16 McCann UD, Kuwabara H, Kumar A. et al. Persistent cognitive and dopamine transporter deficits in abstinent methamphetamine users. Synapse 2008; 62 (02) 91-100.
17 Michelson D, Adler L, Spencer T. et al. Atomoxetine in adults with ADHD: two randomized, placebocontrolled studies. Biol Psychiatry 2003; 53 (02) 112-120.
18 Moore JL, McAuley JW, Long L. et al. An evaluation of the effects of methylphenidate on outcomes in adult epilepsy patients. Epilepsy Behav 2002; 03: 92-95.
19 Mozley PD, Acton PD, Barraclough ED. et al. Effects of age on dopamine transporters in healthy humans. J Nucl Med 1999; 40 (11) 1812-1817.
20 Pliszka SR, McCracken JT, Maas JW. Catecholamines in attention deficit hyperactivity disorder: current perspectives. J Am Acad Child Adolesc Psychiatry 1996; 35 (03) 264-272.
21 Priest RG, Gimbrett R, Roberts M. et al. Reversible and selective inhibitors of monoamine oxidase A in mental and other disorders. Acta Psychiatr Scand Suppl 1995; 386: 40-43.
22 Prince J. Catecholamine dysfunction in attentiondeficit/hyperactivity disorder: an update. J Clin Psychopharmacol 2008; 28 (3 Suppl 2): 2008; S39-45
23 Rösler M, Fischer R, Ammer R. et al. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci 2009; 259 (02) 120-129.
24 Schubiner H, Saules KK, Arfken CL. et al. Doubleblind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10 (03) 286-294.
25 Sevecke K, Döpfner M, Lehmkuhl G. The effectiveness of stimulants of retard forms in children and adolescents with ADHD – a systematic overview. Z Kinder Jugendpsychiatr Psychother 2004; 32 (04) 265-278.
26 Sobanski E, Alm B. Attention deficit hyperactivity disorder in adults: An overview. Nervenarzt 2004; 75 (07) 697-715.
27 Sobanski E, Brüggemann D, Alm B. et al. Psychiatric comorbidity and functional impairment in a clinically referred sample of adults with attention-deficit/hyperactivity disorder (ADHD). Eur Arch Psychiatry Clin Neurosci 2007; 257 (07) 371-377.
28 Solanto MV. Dopamine dysfunction in AD/HD: integrating clinical and basic neuroscience research. Behav Brain Res 2002; 130 (1–2): 65-71.
29 Spencer T, Biederman J, Wilens T. et al. Effectiveness and tolerability of atomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155 (05) 693-695.
30 Swanson JM. Role of executive function in ADHD. J Clin Psychiatry 2003; 64 (Suppl. 14) 35-39.
31 Trott GE, Friese HJ, Menzel M. et al. Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 1992; 106 (Suppl): S134-136.
32 van der Feltz-Cornelis CM, Aldenkamp AP. Effectiveness and safety of methylphenidate in adult attention deficit hyperactivity disorder in patients with epilepsy. An open treatment trial. Epilepsy Behav 2006; 08: 659-662.
33 Volkow ND, Swanson JM. Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am J Psychiatry 2003; 160: 1909-1918.
34 Weisler RH, Biederman J, Spencer TJ. et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr 2006; 11 (08) 625-639.
35 Weiss M, Hechtman L. Adult ADHD Research Group. A randomized double-blind trial of paroxetine and/or dextroamphetamine and problemfocused therapy for attention-deficit/hyperactivity disorder in adults. J Clin Psychiatry 2006; 67 (04) 611-619.
36 Weiss M, Safren SA, Solanto MV. et al. Research forum on psychological treatment of adults with ADHD. J Atten Disord 2008; 11: 642-651.
37 Wender PH, Reimherr FW, Wood D. et al. A controlled study of methylphenidate in the treatment of attention deficit disorder, residual type, in adults. Am J Psychiatry 1985; 142: 547-552.
38 Plener P. et al. Aufmerksamkeitsdefizit-/Hyperaktivitätsstörung und Sport, Pharmakotherapie und Leistungssport. Nervenheilkunde 2010; 29: 14-20.